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Abstract
Objectives: Ceruminous adenoma of the external auditory canal (EAC) is a rare type of tumour that is diagnosed
histologically. However, the clinical behaviour of these tumours remains controversial. Here, we report a case of
ceruminous adenoma of the EAC and expression of a hypoxia marker.
Case report: A 78-year-old man presented with a 6-month history of recurrent otorrhoea in the right ear. Surgery
was performed by the transmeatal approach with total removal of the mass. Histopathology revealed a ceruminous
adenoma. Tumour cells were positive for CK, S-100 protein, Glut-1, HIF-1α, PI3K and p-Akt. There was no evidence of
recurrence at last follow-up 27 months after the operation.
Conclusions: Ceruminous adenoma of the EAC is a rare tumour. The treatment of choice is wide local excision with
clear margins. To our knowledge, this is the first report of Glut-1 expression and the PI3K/Akt pathway in
ceruminous adenoma of the EAC.
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Background
Ceruminous adenoma of the external auditory canal
(EAC) is a rare type of tumour. According to the classifi-
cation of Mills et al. [1], this is a benign lesion and only ap-
proximately 150 cases of ceruminous adenoma at this level
have been reported worldwide to date [2]; consequently,
surgeons and pathologists have little experience with these
neoplasms. Due to the limited number of cases, there has
been considerable confusion regarding the diagnosis, no-
menclature, and behaviour of ceruminous gland neoplasms
[3]. Most cases follow a benign clinical course, and surgical
resection with margins free of neoplasm is typically cura-
tive [1,2]. Some authors have suggested that histological
examination of benign tumours of the EAC cannot predict
biological behaviour and that all tumours should therefore
be treated as potentially malignant [4]. Immunohistochem-
ical staining for proteins such as CK5/6 and S-100 is an
auxiliary method that has contributed to the differential
diagnosis of ceruminous gland tumours [1,5].
The growth of tumours is highly dependent on glucose
as the major energy source. Overexpression of glucose
transporter 1 (Glut-1) has been demonstrated in many
types of human tumour, including some benign tumours,
such as benign salivary gland tumours [6,7], haemangiomas
[8] and nerve sheath tumours [9]. This has also been inter-
preted as an adaptation to intermittent hypoxia, which
occurs as a tumour outgrows its blood supply. In addition
to its role as a glucose transporter, Glut-1 is known to play
an important role in the cellular response to hypoxia, as a
downstream target of hypoxia-inducible factor-1α (HIF-1α).
The HIF complex then binds to hypoxia-responsive ele-
ments (HRE) in target genes and activates their transcrip-
tion. In addition to proline hydroxylation, other regulatory
pathways, including the phosphatidylinositol 3-kinase
(PI3K)/Akt pathway, have been implicated in the control of
HIF-1α protein expression and Glut-1 expression [10,11].
Here, we present a case of ceruminous adenoma in the
EAC expressing Glut-1, HIF-1α, PI3K and p-Akt, which
to our knowledge has not been reported previously in
ceruminous gland tumours.
Case report
A 78-year-old man presented with a 6-month history of re-
current otorrhoea in the right ear. He reported no pain,
hearing loss, tinnitus or vertigo. He had no history of
trauma, surgery or of wearing a hearing aid. Physical
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0.5 × 0.7 cm on the outer part of the right EAC. Palpation
of the mass revealed no tenderness. A computed tomog-
raphy (CT) examination showed a soft lesion measuring
0.5 × 0.5 cm in the right EAC with no sign of bone de-
struction, but the radiologist made a diagnosis of infec-
tion and did not suspect a tumour (Figure 1). Surgery
was performed by the transmeatal approach with total
removal of the mass. Histopathology revealed that the
tumour cells were arranged in a glandular nest, similar
to normal ceruminous glands. The cells were growing
actively, and a diagnosis of adenoma of the ceruminous
gland was made. Immunohistochemical analyses for the
expression of vimentin, cytokeratin (CK), alpha-smooth
muscle actin (α-SMA), desmin, S-100 protein, Glut-1,
HIF-1α, PI3K and p-Akt were performed in the tissue
sample using an EliVision plus IHC Kit (Maixin Bio-
logical, Fuzhou, China). The tumour cells were positive
for CK, S-100 protein, Glut-1, HIF-1α, PI3K and p-Akt
(Figure 2), but negative for all other markers examined.
At final follow-up, 27 months after the operation, there
was no evidence of recurrence.
Discussion and Conclusions
Ceruminous gland tumours are uncommon lesions arising
from the EAC, the behaviour of which is still unclear. In
contrast to the view that most ceruminous gland tumours
can be classified accurately histologically as either benign
or malignant [12], some authors have suggested that all cer-
uminous gland tumours should be regarded as potentially
malignant [4,12]. Complete surgical resection is theFigure 1 CT showed a 0.5×0.5cm soft lesion in the right EAC
with no signs of bone destruction.treatment of choice and is associated with long-term
tumour-free survival. Recurrence on follow-up may occur
[5]. However, there has been no recurrence in our case
after 27 months of follow-up.
The differential diagnosis of ceruminous adenoma
includes ceruminous adenocarcinoma, neuroendocrine
adenoma of the middle ear, parotid pleomorphic aden-
oma, meningioma and paraganglioma [5]. The results of
immunohistochemical analyses are identical to those of
normal cerumen glands, supporting the histogenesis of
this benign neoplasm [1,5]. All adenomas have a dual cell
population, composed of inner luminal epithelial cells
subtended by basal myoepithelial cells adjacent to the
basement membrane. These cell populations are accen-
tuated in immunohistochemical studies; the luminal cells
are strongly immunoreactive for cytokeratin 7, whereas
the basal myoepithelial cells are strongly and diffusely re-
active for S-100 protein [1,5].
In the present case, the neoplastic cells were richer,
showed active growth, and were positive for CK and S-100
protein, suggesting possible roles of these proteins in the
development of these cells. Glut-1 overexpression in
tumour tissue is involved in the cellular response to hyp-
oxia, as a downstream target of HIF-1α [8,13]. Glut-1
upregulation and subsequent overexpression of Glut-1
receptors on the plasma membrane of various tumour
cells are thought to allow escape from the apoptosis-indu-
cing effects of hypoxic environments [8]. HIF-1α modu-
lates the expression of many genes involved in various
processes, such as angiogenesis and pH regulation, and
Glut-1 expression has a central role in this process. PI3K/
AKT signalling plays an important role in the adaptive re-
sponse of tumour cells to hypoxia [14,15]. To some extent,
under the control of AKT, information on AKT activation
status could substantially add to the predictive potential of
endogenous tumour markers (Glut-1, HIF-1α) [10,11,14].
Glut-1, HIF-1α, PI3K and p-Akt expression in neoplastic
cells may be important in the development of a cerumi-
nous adenoma.
In conclusion, ceruminous adenoma of the EAC is rare
type of tumour that is diagnosed histologically. The
treatment of choice is wide local excision with clear mar-
gins. Glut-1, HIF-1α, PI3K and p-Akt expression in neo-
plastic cells may be important for the development of
ceruminous adenoma.
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Figure 2 Immunohistochemistry analyses for the expression of Glut-1, HIF-1α, PI3K and p-Akt. The tumor cells were positive for Glut-1(A)
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